Form 6-K GLAXOSMITHKLINE PLC For: Jul 19
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For period ending 19 July 2016
GlaxoSmithKline plc
(Name of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
Form 20-F x Form 40-F
--
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes No x
--
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. |
Details of PDMR/person closely associated with them ('PCA') | ||
a) |
Name |
Sir Andrew Witty | |
b) |
Position/status |
CEO | |
c) |
Initial notification/
amendment |
Initial notification | |
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) |
Name |
GlaxoSmithKline plc | |
b) |
LEI |
5493000HZTVUYLO1D793 | |
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||
a) |
Description of
The financial
instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |
b) |
Nature of
The transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 14 July 2016 on Ordinary Shares held in the Company's 2009 Performance Share Plan. | |
c) |
Price(s)
and volume(s) |
Price(s) |
Volume(s) |
£16.285 |
3.975 | ||
£16.285 |
217.131 | ||
£16.285 |
580.125 | ||
£16.285 |
1,329.326 | ||
£16.285 |
3,988.006 | ||
£16.285 |
5,452.053 | ||
£16.285 |
5,905.210 | ||
d) |
Aggregated
information
Aggregated volume
Price |
17,475.826
£16.285 | |
e) |
Date of the
transaction |
2016-07-14 | |
f) |
Place of
the transaction
|
n/a |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
GlaxoSmithKline plc
(Registrant)
Date: July 19, 2016
By: VICTORIA WHYTE
----------------------
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Blue Island Homes Chosen as Exclusive Listing Brokers for Ocean Watch at Harbor Pointe: A Premier Gated Waterfront Living Experience in Freeport, New York
- T-Mobile Announces $163 Million in Completed Network Upgrades for Arkansas
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!